Nanomedicine-based drug delivery strategies for the treatment of atherosclerosis

Atherosclerosis, a highly prevalent cardiovascular disease, has significantly contributed to morbidity and mortality worldwide. Despite the availability of various treatment options in clinical practice, complete reversal of the atherosclerotic pathological process remains challenging. Traditional a...

Full description

Saved in:
Bibliographic Details
Main Authors: Yongfang Lin (Author), Ruibo Lin (Author), Han-Bin Lin (Author), Shiyang Shen (Author)
Format: Book
Published: Elsevier, 2024-06-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000 am a22000003u 4500
001 doaj_28e6e9d3f19e4744a49f71bcf47f5852
042 |a dc 
100 1 0 |a Yongfang Lin  |e author 
700 1 0 |a Ruibo Lin  |e author 
700 1 0 |a Han-Bin Lin  |e author 
700 1 0 |a Shiyang Shen  |e author 
245 0 0 |a Nanomedicine-based drug delivery strategies for the treatment of atherosclerosis 
260 |b Elsevier,   |c 2024-06-01T00:00:00Z. 
500 |a 2590-0986 
500 |a 10.1016/j.medidd.2024.100189 
520 |a Atherosclerosis, a highly prevalent cardiovascular disease, has significantly contributed to morbidity and mortality worldwide. Despite the availability of various treatment options in clinical practice, complete reversal of the atherosclerotic pathological process remains challenging. Traditional anti-arteriosclerosis drugs often suffer from poor solubility, limited targeting ability and obvious adverse effects. Additionally, novel therapeutics such as genetic and protein-based drugs inherently suffer from instability issues, thereby compromising their actual curative efficacy and impeding further clinical application. Recently, nanomedicine-based drug delivery strategies have emerged as promising approaches for treating atherosclerosis due to their ability to specifically transport various drugs to target cells, microstructures and specific molecules within lesion sites. These advanced features enhance drug properties and bioavailability while minimizing off-target effects. Moreover, numerous studies have demonstrated that nanomedicine not only inhibits plaque progression but also reduces lesional areas and eventually reverses atherosclerosis. The utilization of nanomedicine is considered an important therapeutic tactic for further mitigating residual risks associated with atherosclerosis. This review provides a comprehensive overview of emerging nanomedicine-based strategies for targeted delivery of anti-atherosclerosis drugs, elucidating their distinct mechanisms and highlighting their remarkable efficacy in combating atherosclerosis. Additionally, critical challenges and future perspectives associated with the development and application of anti-arteriosclerosis nanomedicine are thoroughly discussed. 
546 |a EN 
690 |a Nanomedicine 
690 |a Drug carrier 
690 |a Drug delivery 
690 |a Atherosclerosis treatment 
690 |a Targeted strategy 
690 |a Pharmacy and materia medica 
690 |a RS1-441 
655 7 |a article  |2 local 
786 0 |n Medicine in Drug Discovery, Vol 22, Iss , Pp 100189- (2024) 
787 0 |n http://www.sciencedirect.com/science/article/pii/S2590098624000149 
787 0 |n https://doaj.org/toc/2590-0986 
856 4 1 |u https://doaj.org/article/28e6e9d3f19e4744a49f71bcf47f5852  |z Connect to this object online.